December 26, 2025New England Journal of Medicine
Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia
Key result
Olezarsen treatment for moderate hypertriglyceridemia was associated with mild but significant elevations in aminotransferase levels, potentially due to impaired hepatocellular fatty acid handling.
Why the study?
Does olezarsen cause hepatocellular injury or elevate aminotransferase levels in patients with moderate hypertriglyceridemia?
Population
Patients with moderate hypertriglyceridemia
Design
Editorial
Authors
Discussion
Loading...
Member takes
Implication
While olezarsen represents an advance in treating moderate hypertriglyceridemia, its mechanism of inhibiting hepatic triglyceride production may paradoxically increase hepatic lipotoxic stress and cause mild elevations in aminotransferase levels.
Structured PICO
Does olezarsen cause hepatocellular injury or elevate aminotransferase levels in patients with moderate hypertriglyceridemia?
P
Population
Patients with moderate hypertriglyceridemia
I
Intervention
Olezarsen
While olezarsen represents an advance in treating moderate hypertriglyceridemia, its mechanism of inhibiting hepatic triglyceride production may paradoxically increase hepatic lipotoxic stress and cause mild elevations in aminotransferase levels.
Cite This Study
Bergmark et al. (2025) conducted a letter in moderate hypertriglyceridemia. Olezarsen was evaluated. Olezarsen treatment for moderate hypertriglyceridemia was associated with mild but significant elevations in aminotransferase levels, potentially due to impaired hepatocellular fatty acid handling.